Voloridge Investment Management
URGN icon

Voloridge Investment Management’s UroGen Pharma URGN Stock Holding History

Voloridge Investment Management’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.15M Sell
230,630
-204,860
-47% -$4.11M 0.02% 709
2025
Q4 		$10.2M Sell
435,490
-251,985
-37% -$5.47M 0.04% 574
2025
Q3 		$13.7M Buy
+687,475
New +$12.3M 0.05% 451
2019
Q2 		– Sell
-5,970
Closed -$221K – 1090
2019
Q1 		$221K Buy
+5,970
New +$250K 0.01% 876

Other funds holding URGN

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Voloridge Investment Management's URGN Position: Q1 2026 in Review

Voloridge Investment Management reduced its UroGen Pharma (URGN) stake by 47% in Q1 2026, selling an estimated $4.11M and leaving 230,630 shares worth $4.15M. The position accounts for 0.02% of the portfolio, ranked #709.

Voloridge Investment Management first reported a position in URGN in Q1 2019 and has held it in 4 quarters since. The position peaked at $13.7M in Q3 2025. 173 funds tracked by Wall St. Rank hold URGN as of Q1 2026.

  • Voloridge Investment Management held 230,630 shares of UroGen Pharma worth $4.15M as of Q1 2026.
  • Voloridge Investment Management sold 204,860 UroGen Pharma shares in Q1 2026, an estimated $4.11M.
  • UroGen Pharma made up 0.02% of Voloridge Investment Management's portfolio in Q1 2026, its #709 holding.
  • Voloridge Investment Management first reported a position in UroGen Pharma in Q1 2019 and has held it in 4 quarters since.
  • Voloridge Investment Management's UroGen Pharma position peaked at $13.7M in Q3 2025.
  • 173 funds tracked by Wall St. Rank held UroGen Pharma as of Q1 2026.

Based on Voloridge Investment Management's 13F filing for Q1 2026, filed 15 May 2026.